清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Cisplatin-Based Combinations-Associated Vasculopathy - A Disproportionality Analysis of Real-World Pharmacovigilance Data

医学 药物警戒 顺铂 药理学 肿瘤科 重症监护医学 内科学 药品 化疗
作者
Krutarth K Pandya,Chitsimran Mann,Wei Fang,Brijesh D. Patel
出处
期刊:Current Drug Safety [Bentham Science Publishers]
卷期号:21 (1): 38-44
标识
DOI:10.2174/0115748863312388240829190436
摘要

INTRODUCTION: Cisplatin, a platinum-based antineoplastic agent belonging to the alkylating class, is one of the most widely used chemotherapeutic agents in the treatment of solid tumors and hematologic malignancies. Cisplatin works by forming covalent bonds in DNA, resulting in cell cycle arrest, inadequate repair, and ultimately, apoptotic or non-apoptotic cell death. Despite its efficacy, cisplatin is known to be highly toxic, showing nephrological, Gastrointestinal (GI), and hepatotoxicity, but there is limited data on its association with adverse vascular events. Hence, we aimed to investigate the potential risk of drug-related adverse vascular events associated with four cisplatin-based combination therapies using the FDA Adverse Events Reporting System (FAERS). METHODS: We used the FDA Adverse Events Reporting System (FAERS) database to look for reported Adverse Events (AEs) for cisplatin-based combinations. In the current study, a case/non-case disproportionality analysis has been performed using the Reporting Odds Ratio (ROR) to investigate whether there is a signal for a potentially increased risk of drug-related vascular AE using the 2016-2020 FAERS datasets. To look for all vascular AEs, we included peripheral vascular events, cerebrovascular events, coronary artery-related events, venothromboembolic events, and other arterial events. "Cases" were defined as patients treated with cisplatin and any one of etoposide, gemcitabine, paclitaxel or docetaxel, and 5-fluorouracil or capecitabine, and have reported a composite event. Hence, cases were divided into 4 groups. Reporting Odds Ratio (ROR) and Information Component (IC) were derived to look for signals for these AEs being significant when compared to non-cases. All data processing and statistical analyses were performed using R 4.2.1. RESULTS: Between 2016 and 2020, 23,513 AEs were reported for patients who used cisplatinbased combinations, and 6,952,691 AEs in patients who did not. Baseline characteristics, including age, sex, and geographic distribution, were also reported. Looking at ROR and IC, all 4 groups showed statistically significant vasculopathies reported for cisplatin-based combinations, except for cisplatin and paclitaxel/docetaxel where there was a trend in ROR, but it did not reach statistical significance. It also gave the least signal for associated vasculopathy, while cisplatin and gemcitabine gave the highest signal with both ROR and IC for associated vasculopathy. CONCLUSION: Overall, these increased vasculopathies related to the use of cisplatin-based combinations can be related to the increased pro-thrombotic state in these patients. The results of this study highlight the need for caution when using cisplatin-based chemotherapy and the importance of monitoring patients for thrombotic events and other vasculopathies. Patient-specific factors, such as the type and stage of cancer, should be considered when determining the best treatment option and managing the risk of vascular complications.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
体贴的小霜完成签到,获得积分10
10秒前
11秒前
精明的彩虹完成签到,获得积分10
13秒前
科研通AI6.4的应助被纯情的阁采纳,获得10
15秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
16秒前
所所的应助被纯情的阁采纳,获得30
16秒前
16秒前
顺心安雁完成签到,获得积分10
20秒前
24秒前
27秒前
桐桐的应助被西红柿采纳,获得10
31秒前
33秒前
Qian完成签到 ,获得积分10
33秒前
动听一德完成签到,获得积分10
39秒前
39秒前
无语的羞花完成签到,获得积分10
40秒前
48秒前
49秒前
纯情的阁发布了新的文献求助10
50秒前
50秒前
纯情的阁发布了新的文献求助30
52秒前
纯情的阁发布了新的文献求助10
56秒前
56秒前
纯情的阁发布了新的文献求助10
58秒前
58秒前
缥缈的鸡翅完成签到,获得积分10
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
故意的冷安完成签到,获得积分10
1分钟前
1分钟前
坚定的咖啡完成签到,获得积分10
1分钟前
冷艳千柳完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得30
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
池雨完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158905
求助须知:如何正确求助?哪些是违规求助? 9554522
关于积分的说明 21719373
捐赠科研通 7748459
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552006
邀请新用户注册赠送积分活动 2471370